Stay updated with breaking news from Transform Patient. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase 2 study shows 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 62% relative reduction in the rate of decline in percent predicted forced vital capacity versus... | May 22, 2023
PRINCETON - Bristol Myers Squibb today announced that the European Commission has approved Sotyktu , a first-in-class, selective tyrosine kinase 2 inhibitor, for the treatment of adults with... | March 29, 2023
Sotyktu demonstrated superior efficacy in improving skin clearance over placebo and twice-daily Otezla® , with a well-tolerated safety profile, in the pivotal Phase 3 POETYK PSO clinical... | March 28, 2023
/PRNewswire/ -- Equality Health, a leading provider of value-based physician networks uniquely equipped to address the needs of diverse and historically...
Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu, a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasisNew analysis to be presented at the 2022 European Academy of Dermatology and Venereology Cong...